Otenzepad
![]() Structure of Otenzepad | |
Clinical data | |
---|---|
Routes of administration | oral |
Pharmacokinetic data | |
Bioavailability | 45% (oral)[1] |
Elimination half-life | 2.5h |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.220.541 |
Chemical and physical data | |
Formula | C24H31N5O2 |
Molar mass | 421.545 g·mol−1 |
3D model (JSmol) | |
| |
|
Otenzepad is a competitive muscarinic receptor antagonist that is relatively selective at the M2 receptor. It was investigated as a treatment for arrhythmia and bradycardia due to its cardioselectivity but research ceased after stage III clinical trials. The drug was originally developed by the German pharmaceutical company, Boehringer Ingelheim Pharma KG.[1]
Pharmacodynamics
The (+)-enantiomer has 8 times greater potency at the M2 receptor than the (-)-enantiomer.[1]
mAChR isoform | Dissociation constant (Ki) |
---|---|
M1 | 537.0 - 1300nM[1][2] |
M2 | 81.0 - 186nM[1][2] |
M3 | 838 - 2089.0nM[2][1] |
M4 | 407.0 - 1800nM[1][2] |
M5 | 2800nM[2] |
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.